Increased ubiquitination of multidrug resistance 1 by ginsenoside rd

Nutrition and Cancer

Volumn 62, Issue 2, 2010, Pages 252-259

  Pokharel, Yuba Raj ^a   Kim, Nak Doo ^b   Han, Hyo Kyung ^a   Oh, Won Keun ^a   Kang, Keon Wook ^a  

^a Chosun University   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN BETA; DOXORUBICIN; FORKHEAD TRANSCRIPTION FACTOR; GINSENOSIDE RB 1; GINSENOSIDE RD; GINSENOSIDE RE; GINSENOSIDE RG 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; PREGNANE X RECEPTOR; Y BOX BINDING PROTEIN 1;

ARTICLE; CANCER RESISTANCE; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG MECHANISM; GENE EXPRESSION; GENETIC TRANSCRIPTION; GINSENG; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PROTEIN DEGRADATION; PROTEIN STABILITY; REPORTER GENE; UBIQUITINATION;

BREAST NEOPLASMS; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE; GENE EXPRESSION; GINSENOSIDES; HUMANS; P-GLYCOPROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; UBIQUITINATION;

PANAX GINSENG;

EID: 76749169561     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1080/01635580903407171     Document Type: Article

References (37)

1. Gottesman MM, Fojo T, and Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev 2, 48-58, 2002.
2. Matheny CJ, Lamb MW, Brouwer KR, and Pollack GM: Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation. Pharmacotherapy 21, 778-796, 2001.
3. Modok S, Mellor HR, and Callaghan R:Modulation ofmultidrug resistance efflux pump activity to overcome chemoresistance in cancer. Curr Opin Pharmacol 6, 350-354, 2006.
4. Leonessa F and Clarke R: ATP binding cassette transporters and drug resistance in breast cancer. Endocr Relat Cancer 10, 43-73, 2003.
5. Ernst E: The efficacy of herbalmedicine-an overview. Fundam Clin Pharmacol 19, 405-409, 2005.
6. Tanaka O, Nagai M, and Shibata S: Chemical studies on the oriental plant drugs. XVI. The stereochemistry of protopanaxadiol, a genuine sapogenin of ginseng. Chem Pharm Bull 14, 1150-1156, 1966.
7. Kim SW, Kwon HY, Chi DW, Shim JH, Park JD, Lee YH, Pyo S, and Rhee DK: Reversal of P-glycoprotein-mediated multidrug resistance by ginsenoside Rg3. Biochem Pharmacol 65, 75-82, 2003.
8. Jia WW, Bu X, Philips D, Yan H, Liu G, Chen X, Bush JA, and Li G: Rh2, a compound extracted from ginseng, hypersensitizes multidrug-resistant tumor cells to chemotherapy. Can J Physiol Pharmacol 82, 431-437, 2004.
9. Jin J, Shahi S, Kang HK, van Veen HW, and Fan TP: Metabolites of ginsenosides as novel BCRP inhibitors. Biochem Biophys Res Commun 345, 1308-1314, 2006.
10. Sukhai M, and Piquette-Miller M: Regulation of the multidrug resistance genes by stress signals. J Pharm Phar Sci 3, 268-280, 2000.
11. Zhang Z, Wu JY, Hait WN, and Yang JM: Regulation of the stability of P-glycoprotein by ubiquitination. Mol Pharmacol 66, 395-403, 2004.
12. Han CY, Cho KB, Choi HS, Han HK, and Kang KW: Role of FoxO1 activation in MDR1 expression in adriamycin-resistant breast cancer cells. Carcinogenesis 29, 1837-1844, 2008.
13. Shin JN, SeoYW, Kim M, Park SY, Lee MJ, Lee BR, Oh JW, Seol DW, and Kim TH: Cisplatin inactivation of caspases inhibits death ligand-induced cell death in vitro and fulminant liver damage in mice. J Biol Chem 280, 10509-10515, 2005.
14. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, and Colgan SP: Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 62, 3387-3394, 2002.
15. Han HK,. Han CY, Cheon EP, Lee J, and Kang KW: Role of hypoxiainducible factor-alpha in hepatitis-B-virus X protein-mediated MDR1 activation. Biochem Biophys Res Commun 357, 567-573, 2007.
16. Fujita T, Ito K, Izumi H, Kimura M, Sano M, Nakagomi H, Maeno K, Hama Y, Shingu K, Tsuchiya S, Kohno K, and Fujimori M: Increased nuclear localization of transcription factor Y-box binding protein 1 accompanied by up-regulation of P-glycoprotein in breast cancer pretreated with paclitaxel. Clin Cancer Res 11, 8837-8844, 2005.
17. Chen GK, Sale S, Tan T, Ermoian RP, and Sikic BI: CCAAT/enhancerbinding protein beta (nuclear factor for interleukin 6) transactivates the human MDR1 gene by interaction with an inverted CCAAT box in human cancer cells. Mol Pharmacol 65, 906-916, 2004.
18. Geick A, Eichelbaum M, and Burk O: Nuclear receptor response elements mediate induction of intestinalMDR1by rifampin.JBiolChem276, 14581-14587, 2001.
19. Sun Y: E3 ubiquitin ligases as cancer targets and biomarkers. Neoplasia 8, 645-654, 2006.
20. Maier A, Zimmermann C, Beglinger C, Drewe J, and Gutmann H: Effects of budesonide on P-glycoprotein expression in intestinal cell lines. Br J Pharmacol 150, 361-368, 2007.
21. Yu ST, Chen TM, Tseng SY, and Chen YH: Tryptanthrin inhibits MDR1 and reverses doxorubicin resistance in breast cancer cells. Biochem Biophys Res Commun 358, 79-84, 2007.
22. Cheng Y, Shen LH, and Zhang JT: Anti-amnestic and anti-aging effects of ginsenoside Rg1 and Rb1 and its mechanism of action. Acta Pharmacol Sin 26, 143-149, 2005.
23. Lee KY and Lee SK: Ginsenoside-Rg1 positively regulates cyclin Edependent kinase activity in human hepatoma SK-HEP-1 cells. Biochem. Mol Biol Int 39, 539-546, 1996.
24. Lee KY, Lee YH, Kim SI, Park JH, and Lee SK: Ginsenoside-Rg5 suppresses cyclin E-dependent protein kinase activity via up-regulating p21Cip/WAF1 and down-regulating cyclin E in SK-HEP-1 cells. Anticancer Res 17, 1067-1072, 1997.
25. Oh M, Choi Y.H, Choi S, Chung H, Kim K, Kim SI, Kim DK, and Kim ND: Anti-proliferating effects of ginsenoside Rh2 on MCF-7 human breast cancer cells. Int J Oncol 14, 869-875, 1999.
26. Kim SE, Lee YH, Park JH, and Lee SK: Ginsenoside-Rs4, a new type of ginseng saponin concurrently induces apoptosis and selectively elevates protein levels of p53 and p21WAF1 in human hepatoma SK-HEP-1 cells. Eur J Cancer 35, 507-511, 1999.
27. Kim YS and Jin SH: Ginsenoside Rh2 induces apoptosis via activation of caspase-1 and-3 and up-regulation of Bax in human neuroblastoma. Arch Pharm Res 27, 834-839, 2004.
28. Yue PY, Wong DY, Wu PK, Leung PY, Mak NK, Yeung HW, Liu L, Cai Z, Jiang ZH, Fan TP, and Wong RN: The angiosuppressive effects of 20(R)-ginsenoside Rg3. Biochem Pharmacol 72, 437-445, 2006.
29. McDevitt CA and Callaghan R: How can we best use structural information on P-glycoprotein to design inhibitors? Pharmacol Ther 113, 429-441, 2007.
30. Zhou J, Liu M, Aneja R, Chandra R, Lage H, and Joshi HC: Reversal of P-glycoprotein-mediated multidrug resistance in cancer cells by the c-Jun NH2-terminal kinase. Cancer Res 66, 445-452, 2006.
31. Lu MC, Lai TY, Hwang JM, Chen HT, Chang SH, Tsai FJ, Wang HL, Lin CC,KuoWW, Huang CY: Proliferation-andmigration-enhancing effects of ginseng and ginsenosideRg1 through IGF-I-and FGF-2-signaling pathways on RSC96 Schwann cells. Cell Biochem Funct 27, 186-192, 2009.
32. Shi AW, Wang XB, Lu FX, Zhu MM, Kong XQ, Cao KJ: Ginsenoside Rg1 promotes endothelial progenitor cell migration and proliferation. Acta Pharmacol Sin 30, 299-306, 2009.
33. Lu XZ, Wang JH, Wu X, Zhou L, Wang L, Zhang XW, Cao KJ, Huang J: Ginsenoside Rg1 promotes bone marrow stromal cells proliferation via the activation of the estrogen receptor-mediated signaling pathway. Acta Pharmacol Sin 29, 1209-1214, 2008.
34. Shtil AA: Signal transduction pathways and transcriptional mechanisms as targets for prevention of emergence of multidrug resistance in human cancer cells. Curr Drug Targets 2, 57-77, 2001.
35. Lee YJ, Chung E, Lee KY, Lee YH, Huh B, and Lee SK: Ginsenoside-Rg1, one of the major active molecules from Panax ginseng, is a functional ligand of glucocorticoid receptor. Mol Cell Endocrinol 133, 135-140, 1997.
36. Leung KW, Leung FP, Huang Y, Mak NK, and Wong RN: Non-genomic effects of ginsenoside-Re in endothelial cells via glucocorticoid receptor. FEBS Lett 581, 2423-2428, 2007.
37. Jeong JH, An JY, Kwon YT, Li LY, and Lee YJ: Quercetin-induced ubiquitination and down-regulation of Her-2/neu. J Cell Biochem 105, 585-595, 2008.